依洛尤单抗降低低密度脂蛋白胆固醇对外周动脉疾病患者结局的影响:FOURIER 试验分析
依洛尤单抗在 PAD 患者中一致降低主要终点(HR 0.79)和关键次要终点(HR 0.73),且绝对风险降幅更大;同时降低主要不良肢体事件风险(HR 0.58)。
要点
- PAD 患者心血管风险高,依洛尤单抗治疗绝对风险降幅更大。
- 依洛尤单抗降低主要不良肢体事件风险(HR 0.58)。
- 更低 achieved LDL-C 与更低肢体事件风险相关,延伸至 <10 mg/dL。
核心结论
- PAD 患者心血管事件风险高,依洛尤单抗显著降低该风险且绝对风险降幅大。
- 依洛尤单抗降低 LDL-C 同时减少主要不良肢体事件风险。
主要发现
- PAD 患者主要终点 HR 0.79(95%CI 0.66-0.94;P=0.0098),无 PAD 患者 HR 0.86(95%CI 0.80-0.93;P=0.0003),交互 P=0.40。
- PAD 患者关键次要终点 HR 0.73(95%CI 0.59-0.91;P=0.0040),无 PAD 患者 HR 0.81(95%CI 0.73-0.90;P<0.0001),交互 P=0.41。
- PAD 患者主要终点绝对风险降幅 3.5%,无 PAD 患者 1.6%;关键次要终点绝对风险降幅分别为 3.5% 和 1.4%。
- 依洛尤单抗降低所有患者主要不良肢体事件风险(HR 0.58;95%CI 0.38-0.88;P=0.0093),在有无 PAD 者中效果一致。
- 更低 achieved LDL-C 与更低肢体事件风险相关(β 系数 P=0.026),延伸至 <10 mg/dL。
临床怎么用
- 对合并 PAD 的动脉粥样硬化患者,可考虑依洛尤单抗强化降脂以降低心血管和肢体事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events. METHODS: FOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients with atherosclerotic disease on statin therapy followed for a median of 2.2 years. Patients were identified as having PAD at baseline if they had intermittent claudication and an ankle brachial index of <0.85, or if they had a prior peripheral vascular procedure. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina, or coronary revascularization. The key secondary end point was a composite of cardiovascular death, myocardial infarction, or stroke. An additional outcome of interest was major adverse limb events defined as acute limb ischemia, major amputation, or urgent peripheral revascularization for ischemia. RESULTS: Three thousand six hundred forty-two patients (13.2%) had PAD (1505 with no prior myocardial infarction or stroke). Evolocumab significantly reduced the primary end point consistently in patients with PAD (hazard ratio [HR] 0.79; 95% confidence interval [CI], 0.66-0.94; P=0.0098) and without PAD (HR 0.86; 95% CI, 0.80-0.93; P=0.0003; Pinteraction=0.40). For the key secondary end point, the HRs were 0.73 (0.59-0.91; P=0.0040) for those with PAD and 0.81 (0.73-0.90; P<0.0001) for those without PAD (Pinteraction=0.41). Because of their higher risk, patients with PAD had larger absolute risk reductions for the primary end point (3.5% with PAD, 1.6% without PAD) and the key secondary end point (3.5% with PAD, 1.4% without PAD). Evolocumab reduced the risk of major adverse limb events in all patients (HR, 0.58; 95% CI, 0.38-0.88; P=0.0093) with consistent effects in those with and without known PAD. There was a consistent relationship between lower achieved low-density lipoprotein cholesterol and lower risk of limb events (P=0.026 for the beta coefficient) that extended down to <10 mg/dL. CONCLUSIONS: Patients with PAD are at high risk of cardiovascular events, and PCSK9 inhibition with evolocumab significantly reduced that risk with large absolute risk reductions. Moreover, lowering of low-density lipoprotein cholesterol with evolocumab reduced the risk of major adverse limb events. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01764633.
引用
- Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2017. PMID: 29133605. doi:10.1161/CIRCULATIONAHA.117.032235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。